Disc Medicine, Inc. Capital Expenditures Incurred but Not yet Paid
Disc Medicine, Inc. (IRON) reported Capital Expenditures Incurred but Not yet Paid of $245.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-02-27
- Disc Medicine, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Disc Medicine, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-12-31 was $9.00K.
- Disc Medicine, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $8.00K, a 27.27% decline year-over-year.
- Disc Medicine, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Disc Medicine, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $245.00K, a 1784.62% increase from fiscal 2023.
- Disc Medicine, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $13.00K.
- Disc Medicine, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Disc Medicine, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $10.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2024-12-31 | $245.00K 10-K · filed 2025-02-27 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $9.00K derived: sum of 2 quarters · filed 2025-02-27 | ||
| 2023-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $13.00K 10-K · filed 2025-02-27 | ||
| 2023-09-30 | $4.00K 10-Q · filed 2023-11-09 | |||
| 2023-03-31 | $8.00K 10-Q · filed 2024-05-09 | $8.00K derived: sum of 2 quarters · filed 2024-05-09 | $8.00K derived: sum of 3 quarters · filed 2024-05-09 | -$3.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | -$11.00K derived: sum of 3 quarters · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$11.00K derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $1.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $1.00K derived: sum of 3 quarters · filed 2023-05-15 | -$51.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-03-31 | $11.00K 10-Q · filed 2023-05-15 | $12.00K derived: sum of 2 quarters · filed 2023-05-15 | -$40.00K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$51.00K derived: sum of 2 quarters · filed 2023-03-31 | $10.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $9.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $61.00K 10-Q · filed 2022-08-11 | |||
| 2020-06-30 | $22.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |